GV-971 attenuates α-Synuclein aggregation and related pathology.

Zhenwei YuYing YangRobin Barry ChanMin ShiTessandra StewartYang HuangZongran LiuGuoyu LanLifu ShengChen TianDishun YangJing Zhang

Published in: CNS neuroscience & therapeutics (2023)

mice. Furthermore, GV-971 corrected α-syn-induced inhibition of EVs release in neurons, contributing to neuronal protection. Future studies are needed to further assess GV-971 as a promising disease-modifying therapy for PD and other synucleinopathies.

Keyphrases

high glucose
diabetic rats
spinal cord
drug induced
current status
high fat diet induced
case control
type diabetes
skeletal muscle
spinal cord injury